Drug Trial Radar · NCT07174297
Acotiamide vs Itopride in Postprandial Distress Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Oct 30, 2025
Primary completion
Dec 30, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Getz PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Rawalpindi Medical College, Pakistan
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to "To compare the efficacy and safety of Acotiamide versus Itopride in patient with post prandial distress syndrome type of functional dyspepsia"
Conditions
- Postprandial Distress Syndrome
Interventions
AcotiamideDrug
Both these drugs are used for the management of PDS type of FD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in overall treatment effect between both groups by using Leuven Postprandial Distress Scale in 8 weeksTime frame: 8 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.